Quarterly report pursuant to Section 13 or 15(d)

SEGMENT REPORTING (Tables)

v3.20.2
SEGMENT REPORTING (Tables)
9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
   

BioSig

Technologies, Inc

   

ViralClear

Pharmaceuticals, Inc.

   

NeuroClear

Technologies,

Inc.

   

Total

 

Operating expenses:

                               

Research and development

  $ 698,310     $ 4,182,887     $ 29,630     $ 4,910,827  

General and administrative

    6,807,422       1,357,805       261       8,165,488  

Depreciation and amortization

    23,012       -       857       23,869  

    Total operating expenses

    7,528,744       5,540,692       30,748       13,100,184  
                                 

Loss from Operations

    (7,528,744

)

    (5,540,692

)

    (30,748

)

    (13,100,184

)

                                 

Other income:

                               

Interest income and other income, net

    1,453       290       -       1,743  
                                 

Net loss

  $ (7,527,291

)

  $ (5,540,402

)

  $ (30,748

)

  $ (13,098,441

)

 

   

BioSig

Technologies, Inc

   

ViralClear

Pharmaceuticals, Inc.

   

NeuroClear

Technologies,

Inc.

   

Total

 

Operating expenses:

                               

Research and development

  $ 3,112,294     $ 12,413,801     $ 29,630     $ 15,555,725  

General and administrative

    18,755,512       13,873,146       261       32,628,919  

Depreciation and amortization

    66,235       -       857       67,092  

    Total operating expenses

    21,934,041       26,286,947       30,748       48,251,736  
                                 

Loss from Operations

    (21,934,041

)

    (26,286,947

)

    (30,748

)

    (48,251,736

)

                                 

Other income:

                               

Interest income and other income, net

    28,915       14,697       -       43,612  
                                 

Net loss

  $ (21,905,126

)

  $ (26,272,250

)

  $ (30,748

)

  $ (48,208,124

)